| 1 |
Neofytos D, Garcia-Vidal C, Lamoth F, et al.Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment,and assessment of response[J].BMC Infect Dis, 2021, 21(1):296.
|
| 2 |
姜雪, 顾鹏, 许书添.肾移植受者感染的流行病学特点和危险因素[J].肾脏病与透析肾移植杂志,2019,28(6):501-506.
|
| 3 |
沈雁冰, 冯芳, 谢迎春.肾移植术后肺部真菌感染的临床分析[J].中华医院感染学杂志,2011,21(12):2461-2461.
|
| 4 |
刘丁.肾移植术后侵袭性肺部真菌感染的临床研究[D].广东:南方医科大学,2011.
|
| 5 |
中华医学会器官移植学分会, 中国医师协会器官移植医师分会.中国实体器官移植受者侵袭性真菌病临床诊治指南(2016 年版)[J].中华器官移植杂志,2016,37(5):300-305.
|
| 6 |
中华医学会器官移植学分会.器官移植受者侵袭性真菌病临床诊疗技术规范(2019 版)[J].器官移植,2019,10(3):227-236.
|
| 7 |
Husain S, Camargo JF.Invasive aspergillosis in solid - organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J].Clin Transplant,2019,33(9): e13544.
|
| 8 |
陈耀龙, 杨克虎, 王小钦, 等.中国制订/修订临床诊疗指南的指导原则(2022 版)[J].中华医学杂志, 2022, 102(10):697-703.
|
| 9 |
Howick J.The Oxford 2011 levels of evidence[EB/OL].[2024-3-24].http:/ /www cebm net/index aspx? o= 5653,2011.
|
| 10 |
刘炎忠, 柏宏伟, 石炳毅, 等.老年肾移植受者肺部感染的危险因素分析[J].中华器官移植杂志,2020,41(4):247-251.
|
| 11 |
Pérez-Jacoiste Asín MA, López-Medrano F, Fernández-Ruiz M, et al.Risk factors for the development of invasive aspergillosis after kidney transplantation: systematic review and meta-analysis[J].Am J Transplant,2021,21(2):703-716.
|
| 12 |
López-Medrano F, Silva JT, Fernández-Ruiz M, et al.Risk factors associated with early invasive pulmonary aspergillosis in kidney transplant recipients: results from a multinational matched casecontrol study[J].Am J Transplant,2016,16(7):2148-2157.
|
| 13 |
Friedman DZ, Johnson BK, Beam E, et al.Risk factors and outcomes of invasive aspergillosis in kidney transplant recipients: a case-control study of United States renal data system data[J].Clin Infect Dis,2023,76(8):1431-1439.
|
| 14 |
Pennington KM, Martin MJ, Murad MH, et al.Risk factors for early fungal disease in solid organ transplant recipients: a systematic review and meta-analysis[J].Transplantation,2024,108(4):970-984.
|
| 15 |
Machado M,Fortún J,Muñoz P.Invasive aspergillosis:a comprehensive review[J].Med Clin (Barc),2024,163(4):189-198.
|
| 16 |
Wang Y, Cui X, Tian R, et al.The epidemiological characteristics of invasive pulmonary aspergillosis and risk factors for treatment failure: a retrospective study[J].BMC Pulm Med, 2024, 24(1):559.
|
| 17 |
López-Medrano F, Fernández-Ruiz M, Silva JT, et al.Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation[J].Clin Microbiol Infect,2018,24(2):192-198.
|
| 18 |
Neofytos D, Chatzis O, Nasioudis D, et al.Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study[J].Transpl Infect Dis,2018,20(4): e12898.
|
| 19 |
Freeman RB Jr.The ‘indirect’effects of cytomegalovirus infection[J].Am J Transplant,2009,9(11):2453-2458.
|
| 20 |
L′huillier AG, Ferreira VH, Ku T, et al.Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients[J].Am J Transplant,2019,19(9):2495-2504.
|
| 21 |
邱涛, 周江桥, 陈忠宝, 等.肾移植术后再次手术的临床分析[J].中华器官移植杂志,2018,39(8):475-478.
|
| 22 |
Sigera LSM, Denning DW.Invasive aspergillosis after renal transplantation[J].J Fungi (Basel),2023,9(2):255.
|
| 23 |
谭可平, 李锦宏, 陆晖, 等.肾移植术后肺部真菌感染的临床特征及危险因素分析[J/CD].实用器官移植电子杂志, 2021, 9(5):376-381.
|
| 24 |
Fernández-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature[J].Medicine,2012,91(5):261-273.
|
| 25 |
Balcan B, Ozcelik U, Ugurlu AO, et al.Increased mortality among renal transplant patients with invasive pulmonary Aspergillus infection[J].Prog Transplant,2018,28(4):349-353.
|
| 26 |
Trabelsi H, Néji S, Sellami H, et al.Invasive fungal infections in renal transplant recipients: about 11 cases[J].J Mycol Med,2013,23(4):255-260.
|
| 27 |
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al.Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J].Clin Microbiol Infect, 2018,24(Suppl 1):e1-e38.
|
| 28 |
Alexander BD, Lamoth F, Heussel CP, et al.Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC[J].Clin Infect Dis,2021,72(Suppl 2):S79-S88.
|
| 29 |
López-Medrano F, Fernández- Ruiz M, Silva J, et al.Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study[J].Am J Transplant,2016,16(11):3220-3234.
|
| 30 |
Song N, Li X, Liu W.Metagenomic next-generation sequencing(mNGS) for diagnosis of invasive fungal infectious diseases: a narrative review[J].J Lab Precis Med,2021,6:29.
|
| 31 |
Pfeiffer CD, Fine JP, Safdar N.Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis[J].Clin Infect Dis,2006,42(10):1417-1727.
|
| 32 |
Husain S, Kwak EJ, Obman A, et al.Prospective assessment of Platelia? Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients [ J].Am J Transplant,2004,4(5):796-802.
|
| 33 |
Li C, Sun L, Liu Y, et al.Diagnostic value of bronchoalveolar lavage fluid galactomannan assay for invasive pulmonary aspergillosis in adults: a meta-analysis[J].J Clin Pharm Ther, 2022, 47(12):1913-1922.
|
| 34 |
Singh N, Winston DJ, Limaye AP, et al.Performance characteristics of galactomannan and β-d-glucan in high-risk liver transplant recipients[J].Transplantation,2015,99(12):2543-2550.
|
| 35 |
Zhang L, Guo Z, Xie S, et al.The performance of galactomannan in combination with 1, 3-β-D-glucan or Aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: evidences from 13 studies[J].Diagn Microbiol Infect Dis,2019,93(1):44-53.
|
| 36 |
Han Y, Wu X, Jiang G, et al.Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnostic meta-analysis[J].BMC Pulm Med,2023,23(1):58.
|
| 37 |
Cruciani M, White PL, Mengoli C, et al.The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis[J].J Antimicrob Chemother, 2021, 76(3):635-638.
|
| 38 |
梁珊, 吴潇潇, 高瞻, 等.移植术常见病原体检测的多联qPCR法的建立与初步应用[J].中国输血杂志, 2022, 35(5):494-500.
|
| 39 |
Ledoux MP, Guffroy B, Nivoix Y, et al.Invasive pulmonary aspergillosis[J].Semin Respir Crit Care Med, 2020, 41(1):80-98.
|
| 40 |
Jenks JD, Prattes J, Frank J, et al.Performance of the bronchoalveolar lavage fluid aspergillus galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study[J].Clin Infect Dis, 2021,73(7): e1737-e1744.
|
| 41 |
Arkell P, Mahboobani S, Wilson R, et al.Bronchoalveolar lavage fluid IMMY Sona Aspergillus lateral-flow assay for the diagnosis of invasive pulmonary aspergillosis: a prospective, real life evaluation[J].Med Mycol,2021,59(4):404-408.
|
| 42 |
Li H.Editorial: mNGS for fungal pulmonary infection diagnostics[J].Front Cell Infect Microbiol,2022,12:864163.
|
| 43 |
Ma X, Zhang S, Xing H, et al.Invasive pulmonary aspergillosis diagnosis via peripheral blood metagenomic next-generation sequencing[J].Front Med (Lausanne),2022,9:751617.
|
| 44 |
孟现林, 张蕾, 范骁钦, 等.宏基因组二代测序技术检测支气管肺泡灌洗液中病原体对器官移植患者肺部感染的诊断价值[J].中华危重病急救医学,2021,33(12):1440-1446.
|
| 45 |
Dichtl K, Seybold U, Ormanns S, et al.Evaluation of a novel Aspergillus antigen enzyme-linked immunosorbent assay[J].J Clin Microbiol,2019,57(7): e00136-19.
|
| 46 |
Aerts R, Mercier T, Houben E, et al.Performance of the JF5-based galactomannoprotein EIA compared to the lateral flow device and the galactomannan EIA in serum and bronchoalveolar lavage fluid[J].J Clin Microbiol,2022,60(11):e0094822.
|
| 47 |
Herbrecht R, Denning DW, Patterson TF, et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347(6):408-415.
|
| 48 |
Maertens JA, Rahav G, Lee DG, et al.Posaconazole versus voriconazole for primary treatment of invasive aspergillosis:a phase 3,randomised, controlled, non-inferiority trial[J].Lancet,2021,397(10273):499-509.
|
| 49 |
Maertens JA, Raad II, Marr KA, et al.Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3,randomised-controlled, non-inferiority trial[J].Lancet, 2016, 387(10020):760-769.
|
| 50 |
Heinz WJ, Buchheidt D, Ullmann AJ.Clinical evidence for caspofungin monotherapy in the first - line and salvage therapy of invasive Aspergillus infections[J].Mycoses, 2016, 59(8): 480-493.
|
| 51 |
Welte T, Len O, Muñoz P, et al.Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response[J].Infection,2019,47(6):919-927.
|
| 52 |
Russo A, Giuliano S, Vena A, et al.Predictors of mortality in nonneutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?[J].Diagn Microbiol Infect Dis, 2014,80(1):83-86.
|
| 53 |
Cho HJ, Jang MS, Hong SD, et al.Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis[J].Am J Rhinol Allergy,2015,29(1):48-53.
|
| 54 |
Chai LY, Netea MG, Teerenstra S, et al.Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive aspergillosis[J].J Infect Dis,2010,202(9):1454-1462.
|
| 55 |
Krel M, Petraitis V,Petraitiene R,et al.Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response [ J].Antimicrob Agents Chemother,2014,58(6):3373-3378.
|
| 56 |
Vanhove T, Bouwsma H, Hilbrands L, et al.Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients[J].Am J Transplant, 2017,17(9):2372-2380.
|
| 57 |
Emoto C, Vinks AA, Fukuda T.Risk sssessment of drug-drug interactions of calcineurin inhibitors affecting sirolimus pharmacokinetics in renal transplant patients[J].Ther Drug Monit, 2016, 38(5):607-613.
|
| 58 |
Li X, Hu Q, Xu T.Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis[J].Front Pharmacol,2024,15:1368274.
|
| 59 |
Takesue Y, Hanai Y, Oda K, et al.Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J].Clin Ther,2022,44(12):1604-1623.
|
| 60 |
Zhu LE, Huang HP, Cai YP, et al.Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation[J].Eur J Clin Pharmacol,2022,78(10):1677-1685.
|
| 61 |
中国研究型医院学会肝病专业委员会重症肝病学组, 中华医学会肝病学分会重型肝病与人工肝学组.重症肝病合并侵袭性真菌感染诊治专家共识[J].临床肝胆病杂志, 2022, 38(2):311-317.
|
| 62 |
中华医学会血液学分会抗感染学组.艾沙康唑临床应用专家共识(2023 版)[J].临床血液学杂志,2023,36(5):295-302.
|
| 63 |
McQuinn E, Mochel JP, Borts D, et al.Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs[J].PLoS One,2024,19(7): e0305766.
|
| 64 |
Kovanda LL, Maher R, Hope WW.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis[J].Expert Rev Clin Pharmacol, 2016, 9(7): 887-897.
|
| 65 |
Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, et al.Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp.and triazoles against Aspergillus spp[J].Drug Resist Updat,2013,16(6):81-95.
|
| 66 |
Baddley JW, Marr KA,Andes DR,et al.Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network[J].J Clin Microbiol,2009,47(10):3271-3275.
|
| 67 |
Balajee SA, Kano R, Baddley JW, et al.Molecular identification of Aspergillus species collected for the transplant-associated infection surveillance network[J].J Clin Microbiol, 2009, 47(10): 3138-3141.
|
| 68 |
van der Linden JW, Arendrup MC, Warris A, et al.Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus[J].Emerg Infect Dis,2015,21(6):1041-1044.
|
| 69 |
Montesinos I, Albichr IS, Collinge E, et al.Diagnostic value of serum biomarkers for invasive aspergillosis in haematologic patients[J].J Fungi (Basel),2024,10(9):661.
|
| 70 |
Zhou GJ, Xiong WJ, Xu W, et al.Diversity and anti-infectious components of cultivable rhizosphere fungi derived from three species of astragalus plants in northwestern Yunnan, China[J].J Fungi(Basel),2024,10(11):736.
|
| 71 |
Pacini E, Schelenz S, Abdolrasouli A, et al. Aspergillus calidoustus and Talaromyces columbinus infections in chronic graft-versus-host disease[J].Ann Hematol,2024,103(11):4797-4800.
|
| 72 |
Okoroafor CD, Suryadevara M, Gaba P, et al.A case of Aspergillus calidoustus thoracic spine osteomyelitis[J].Cureus, 2024, 16(7):e65667.
|
| 73 |
Egli A, Fuller J, Humar A, et al.Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis[J].Transplantation,2012,94(4):403-410.
|
| 74 |
He JL, Chen CJ, Liu YH, et al.Austin-type meroterpenoids from fungi reported in the last five decades: a review [J].J Fungi(Basel),2024,10(2):162.
|
| 75 |
Bosetti D, Neofytos D.Invasive aspergillosis and the impact of azoleresistance[J].Curr Fungal Infect Rep,2023,17(2):77-86.
|
| 76 |
Singh N, Limaye AP, Forrest G, et al.Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study[J].Transplantation,2006,81(3):320-326.
|
| 77 |
Lockhart SR, Zimbeck AJ, Baddley JW, et al. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network[J].Antimicrob Agents Chemother,2011,55(8):3944-3946.
|
| 78 |
Steinbach WJ, Marr KA,Anaissie EJ,et al.Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry[J].J Infect,2012,65(5):453-464.
|
| 79 |
Barchiesi F, Mazzocato S,Mazzanti S,et al.Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics,treatment, and outcomes in 116 cases[J].Liver Transpl, 2015, 21(2):204-212.
|
| 80 |
Seroy J, Antiporta P, Grim SA, et al. Aspergillus calidoustus case series and review of the literature[J].Transpl Infect Dis, 2017, 19(5): e12755.
|
| 81 |
Kriegl L, Boyer J, Egger M, et al.Antifungal stewardship in solid organ transplantation [J].Transpl Infect Dis, 2022, 24 (5):e13855.
|
| 82 |
Panackal AA, Parisini E, Proschan M.Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis[J].Int J Infect Dis,2014,28:80-94.
|
| 83 |
Calvo-Cano A, Garduño-Eseverri E, Alastruey-Izquierdo A, et al.Successful treatment of invasive aspergillosis caused by Aspergillus parafelis in a kidney transplant recipient[J].Med Mycol Case Rep,2020,30:35-38.
|
| 84 |
Rea F, Marulli G, Loy M, et al.Salvage right pneumonectomy in a patient with bronchial-pulmonary artery fistula after bilateral sequential lung transplantation[J].J Heart Lung Transplant, 2006,25(11):1383-1386.
|
| 85 |
Scherer M, Fieguth HG, Aybek T, et al.Disseminated Aspergillus fumigatus infection with consecutive mitral valve endocarditis in a lung transplant recipient[J].J Heart Lung Transplant, 2005, 24(12):2297-2300.
|
| 86 |
Patterson TF, Thompson Iii GR, Denning DW, et al.Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2016,63(4): e1-e60.
|
| 87 |
Mu X, Liu K, Li H, et al.Granulocyte-macrophage colonystimulating factor: an immunotarget for sepsis and COVID-19[J].Cell Mol Immunol,2021,18(8):2057-2058.
|
| 88 |
Dale DC, Liles WC, Summer WR, et al.Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases[J].J Infect Dis,1995,172(4):1061-1075.
|
| 89 |
Roilides E, Blake C, Holmes A, et al.Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasoneinduced immunosuppression of antifungal monocyte activity gainst Aspergillus fumigatus hyphae[J].J Med Vet Mycol, 1996, 34(1):63-69.
|
| 90 |
Gaviria JM,van Burik JA,Dale DC,et al.Comparison of interferon-γ,granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens[J].J Infect Dis, 1999,179(4):1038-1041.
|
| 91 |
邓斐文.实体器官移植术后真菌感染的防治[J].器官移植,2022,13(4):448-454.
|
| 92 |
Vanderbeke L, Janssen NA, Bergmans DC, et al.Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial[J].Intensive Care Med,2021,47(6):674-686.
|
| 93 |
Douglas AP, Smibert OC, Bajel A, et al.Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021[J].Intern Med J,2021,51(Suppl 7):S143-S176.
|
| 94 |
Agarwal R, Sehgal IS, Muthu V, et al.Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses[J].Eur Respir J,2024,63(4):2400061.
|
| 95 |
Serris A, Rautemaa-Richardson R, Laranjinha JD, et al.European study of cerebral aspergillosis treated with isavuconazole (ESCAI): a study by the ESCMID Fungal Infection Study Group[J].Clin Infect Dis,2024,79(4):936-943.
|
| 96 |
李聪, 李永俊, 郭小军, 等.肾移植围术期预防真菌感染的临床效果分析[J/CD].实用器官移植电子杂志, 2022, 10(6): 541-545.
|
| 97 |
舒永全, 李颖.卡泊芬净与米卡芬净治疗重症侵袭性真菌感染的临床疗效与药物利用评价[J].实用医院临床杂志, 2012, 9(5):80-82.
|
| 98 |
肖晶, 任志强.卡泊芬净与米卡芬净预防肾移植术后侵袭性真菌感染的疗效和安全性[J].临床合理用药杂志,2022,15(19):106-108.
|
| 99 |
Heylen J, Vanbiervliet Y, Maertens J, et al.Acute invasive pulmonary aspergillosis: clinical presentation and treatment [J].Semin Respir Crit Care Med,2024,45(1):69-87.
|
| 100 |
Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, et al.Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI[J].Enferm Infecc Microbiol Clin(Engl Ed),2019,37(8):535-541.
|
| 101 |
Cordonnier C, Rovira M, Maertens J, et al.Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study [J].Haematologica,2010,95(10):1762.
|